Author | Joel Neal, MD | OncLive

Author | Joel Neal, MD


Dr. Neal Debates Whether Alectinib Will Become the Standard Frontline Therapy for ALK+ NSCLC

August 09, 2017


Joel Neal, MD, an assistant professor of medicine and oncology at Stanford Medicine, discusses whether, if approved by the FDA, alectinib (Alecensa) will become the frontline standard of care for patients with ALK-positive non–small cell lung cancer (NSCLC).